Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 7;21:252. doi: 10.1186/s12935-021-01930-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — HHLA2 expression in ovarian cancer and normal ovary tissue. HHLA2 was stained with anti-HHLA2 antibody, and HHLA2-positive staining was detected in a membranous and cytoplasmic pattern in ovarian cancer and normal ovarian tissue epithelium. a–d represented epithelial ovarian cancer tissue obtained from 64 patients with ovarian cancer who had undergo surgical resection between 2007 and 2011. All patients were treatment-naïve before surgery. The level of HHLA2 expression was graded as intensity of IHC staining in ovarian cancer: A1-A2, absent; B1-B2, weak; C1-C2, moderate; D1-D2, strong. e–h The level of HHLA2 expression was graded as intensity of IHC staining in normal ovarian tissue epithelium: E1-E2, absent; F1-F2, weak; G1-G2, moderate; H1-H2, strong. Magnification: × 100 (A1–H1); × 200 (A2–H2). i The positive rate of HHLA2 expression was higher in normal ovary tissue than that in ovarian cancer. The red column represented the HHLA2 positive group, the blue column represented the HHLA2 negative group. The difference between them is significant.(p < 0.05). j Expression of HHLA2 was frequently decreased in 585 ovarian cancer tissues (Tumor) compared with 8 normal ovary tissue (Normal) samples in the oncomine dataset. k The proportion of HHLA2-positive patients was gradually increased with the improvement of tumour differentiation degree. HHLA2 tended to be expressed in well-differentiated ovarian tumour. The red column represented the HHLA2 positive group, the blue column represented the HHLA2 negative group. The difference between them is significant. (p < 0.05)